What is TissueGen?
Founded in 2000, TissueGen operates at the intersection of advanced nanotechnology and pharmaceutical science. The company specializes in the development of transformative polymeric systems designed to preserve the biological activity of sensitive therapeutics. By focusing on sustained release mechanisms, TissueGen addresses critical challenges in both acute and chronic disease management. Their technological framework is engineered to reduce treatment burdens for patients while simultaneously enhancing clinical outcomes, positioning the firm as a critical player in the evolution of modern drug delivery systems.
How much funding has TissueGen raised?
TissueGen has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in TissueGen
PPP
Public-Private Partnership
What's next for TissueGen?
With the recent influx of capital, TissueGen is expected to prioritize the scaling of its manufacturing capabilities and the expansion of its clinical pipeline. The strategic focus will likely shift toward optimizing long-term delivery solutions for complex biological therapeutics, leveraging their established expertise in polymeric nanotechnology. As the company transitions through this late-stage growth phase, stakeholders anticipate further validation of their delivery platforms through expanded clinical trials and potential partnerships with global pharmaceutical entities, aiming to redefine standards in therapeutic administration.
See full TissueGen company page
